The phase 3 trial evaluated fenfluramine when used as an adjunctive therapy for the treatment of uncontrolled seizures in children and adults aged 1 year to 35 years with CDD.

The Breyanzi REMS program and the Abecma REMS program were established due to the risk of cytokine release syndrome and neurologic toxicities.

Enflonsia is an extended half-life RSV fusion glycoprotein neutralizing monoclonal antibody that is designed to provide durable protection through 5 months.

Novo Nordisk end their partnership with Hims & Hers; update to Vizamyl labeling; autoinjector approved for pediatrics with lupus nephritis; psilocybin shows promise in treatment-resistant depression; ...

About 1 in every 150 people infected develops severe symptoms that can affect the brain, spinal cord and nerves.

The scientist named on the slide, Robert Berman of the University of California-Davis, says he never wrote such a paper.

Michelle Bulls, director of the NIH’s Office of Policy for Extramural Research Administration, said no more grant cancellations should move forward.